{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:05:12Z","timestamp":1782831912223,"version":"3.54.5"},"reference-count":24,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,5,5]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>A woman in her 70s with metastatic melanoma presenting with refractory hypokalaemia on combined immune checkpoint inhibitors, nivolumab\u2013ipilimumab, was diagnosed with adrenocorticotropic hormone (ACTH)-dependent hypercortisolism 11 weeks following the initiation of her immunotherapy. Investigations also demonstrated central hypothyroidism and hypogonadotropic hypogonadism. She underwent imaging studies of her abdomen and brain which revealed normal adrenal glands and pituitary, respectively. She was started on levothyroxine replacement and had close pituitary function monitoring. Two weeks later, her cortisol and ACTH levels started to trend down. She finally developed secondary adrenal insufficiency and was started on hydrocortisone replacement 4\u2009weeks thereafter.<\/jats:p>\n               <jats:p>This report highlights a case of immunotherapy-related hypophysitis with well-documented transient central hypercortisolism followed, within weeks, by profound secondary adrenal insufficiency. Healthcare professionals should remain vigilant in monitoring laboratory progression in these patients. Early recognition of the phase of hypercortisolism and its likely rapid transformation into secondary adrenal insufficiency can facilitate timely hormonal replacement and prevent complications.<\/jats:p>","DOI":"10.1136\/bcr-2023-258701","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T22:45:21Z","timestamp":1716331521000},"page":"e258701","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Immune checkpoint inhibitor-induced hypophysitis with transient ACTH-dependent hypercortisolism"],"prefix":"10.1136","volume":"17","author":[{"given":"Fatima Abdullah","family":"AlRubaish","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8799-1171","authenticated-orcid":false,"given":"Nisha","family":"Gupta","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng Zhu","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Christopoulos","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"2025082701470446000_17.5.e258701.1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"2025082701470446000_17.5.e258701.2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1617941114"},{"key":"2025082701470446000_17.5.e258701.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.05.029"},{"key":"2025082701470446000_17.5.e258701.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2025082701470446000_17.5.e258701.5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025082701470446000_17.5.e258701.6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"2025082701470446000_17.5.e258701.7","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2025082701470446000_17.5.e258701.8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/CMR.0000000000000405","article-title":"Transient pituitary ACTH-dependent cushing syndrome caused by an immune checkpoint inhibitor combination","volume":"27","author":"Lupu","year":"2017","journal-title":"Melanoma Res"},{"key":"2025082701470446000_17.5.e258701.9","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1507\/endocrj.EJ19-0076","article-title":"Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation","volume":"66","author":"Sekizaki","year":"2019","journal-title":"Endocr J"},{"key":"2025082701470446000_17.5.e258701.10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ando.2021.11.007","article-title":"Pembrolizumab-induced cyclic ACTH-dependent cushing\u2019s syndrome treated by a block-and-replace approach with osilodrostat","volume":"83","author":"Paepegaey","year":"2022","journal-title":"Ann Endocrinol (Paris)"},{"key":"2025082701470446000_17.5.e258701.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.011"},{"key":"2025082701470446000_17.5.e258701.12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2025082701470446000_17.5.e258701.13","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ando.2018.07.008","article-title":"Expert opinion on pituitary complications in Immunotherapy","volume":"79","author":"Briet","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"2025082701470446000_17.5.e258701.14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"2025082701470446000_17.5.e258701.15","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0342"},{"key":"2025082701470446000_17.5.e258701.16","doi-asserted-by":"publisher","DOI":"10.1055\/a-0843-3366"},{"key":"2025082701470446000_17.5.e258701.17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment","volume":"14","author":"Di Dalmazi","year":"2019","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2025082701470446000_17.5.e258701.18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2306"},{"key":"2025082701470446000_17.5.e258701.19","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0729-3","article-title":"Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis","volume":"7","author":"Thapi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025082701470446000_17.5.e258701.20","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for Immunotherapy of cancer (Sitc)","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2025082701470446000_17.5.e258701.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025082701470446000_17.5.e258701.22","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0068"},{"key":"2025082701470446000_17.5.e258701.23","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pky021","article-title":"The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management","volume":"2","author":"Girotra","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"2025082701470446000_17.5.e258701.24","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French endocrine society guidance on endocrine side effects of Immunotherapy","volume":"26","author":"Castinetti","year":"2019","journal-title":"Endocr Relat Cancer"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-258701","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:47:13Z","timestamp":1756284433000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-258701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,21]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/bcr-2023-258701"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-258701","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}